Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 13/20 | 0.62 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.61 |
| ▸ | CTSL | P07711 | 3/20 | 0.59 |
| ▸ | CTSS | P25774 | 3/20 | 0.59 |
| ▸ | CTSK | P43235 | 3/20 | 0.59 |
| ▸ | CTSH | P09668 | 1/20 | 0.59 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10346018 | 0.88 | CXCR4 (0.63) | CXCR4C5AR1CTSLCTSSCTSK | |
| SCHEMBL10346020 | 0.88 | CXCR4 (0.63) | CXCR4C5AR1CTSLCTSSCTSK | |
| SCHEMBL29754594 | 0.87 | C5AR1 (0.70) | CXCR4C5AR1CTSLCTSSCTSK | |
| SCHEMBL30165155 | 0.87 | CXCR4 (0.53) | CXCR4C5AR1CTSLCTSSCTSK | |
| SCHEMBL30577312 | 0.87 | C5AR1 (0.63) | CXCR4C5AR1CTSLCTSSCTSK | |
| SCHEMBL31591524 | 0.86 | C5AR1 (0.65) | CXCR4C5AR1CTSLCTSSCTSK | |
| SCHEMBL29551954 | 0.86 | C5AR1 (0.53) | CXCR4C5AR1CTSLCTSSCTSK | |
| SCHEMBL31483961 | 0.85 | C5AR1 (0.59) | CXCR4C5AR1CTSLCTSSCTSK | |
| SCHEMBL7326493 | 0.85 | CXCR4 (0.68) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL30609008 | 0.85 | C5AR1 (0.61) | CXCR4C5AR1CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | GLO PHARMA, INC. | 2024-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNB1, CHRNG, CHRNA1 | CXCR4 1494/4885C5AR1 52/4885CTSL 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.